FEATURE: The promise of 'liquid biopsies' in cancer and beyond
This article was originally published in Clinica
Executive Summary
Being able to diagnose cancer and monitor its progression with just a blood sample, rather than with tumor biopsies, is the aim that companies in the ‘liquid biopsy’ arena are striving for. Madeleine Armstrong finds out more about the different approaches within the field of circulating tumor cell and circulating tumor DNA detection and weighs their pros and cons